{‘She has no experience’: this American scientific establishment braces for Tracy Beth Høeg’s role at the Food and Drug Administration.

As the US proceeds with unprecedented changes to its vaccine recommendations, an unexpected name appears in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations in the pandemic and has concentrated on possible fatalities after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Program

Health officials were set to announce radical revisions to the pediatric vaccination calendar in December, aligning the US with the Danish immunization schedule, according to reports – a major change that would put the US out of alignment with many the global community with no evidence for improved outcomes. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to present at the event. She was just designated acting director of the FDA’s CDER, the fifth individual to head the center this year.

A New Direction at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

Høeg has no obvious track record in drug development, approval processes or leadership, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

This division has an immense range of responsibilities at the agency, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of generic medications. There’s a biosimilars program, over-the-counter program and more, and all of those need to be looked after,” she said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major administrative aspect to the position, which supervises more than 5,000 personnel. “It’s a huge management job, if you execute it properly,” she added.

Agency Reaction and Contentious Policies

In response to questions about Høeg’s fitness for the role and whether this selection represents greater collaboration among agency officials on vaccines, a representative stated that the “inquiries rely on incorrect assumptions”.

“Her resume aligns with the duties of her position,” the spokesperson explained, noting the period Dr. Høeg spent counseling the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a controversial rapid drug-approval program that allegedly worried her preceding directors. “How are these drugs being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There’s a lot of confidentiality going on at the agency right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer rules of most medications, aside from shots.”

Public History on Vaccines

Concerning immunizations, Høeg has a more documented, if troubling, history, some experts observe. She authored a research paper using non-validated volunteer-provided data to assess the incidence of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the new administration encompassed revising guidelines for recently developed shots and halting “unnecessary” immunizations, she remarked following the vote on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccines.

“She’s an complete true believer who begins with her preconceived notions and reverse-engineers to accommodate the data in a highly misleading, dishonest manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|